US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
JPH10501811A
(en)
*
|
1994-06-20 |
1998-02-17 |
シェーリング コーポレイション |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
MX9802377A
(en)
*
|
1995-09-27 |
1998-08-30 |
Schering Corp |
Stereoselective microbial reduction process.
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
EP0766962A3
(en)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Treatment of atherosclerosis
|
GEP20033006B
(en)
*
|
1995-10-31 |
2003-07-10 |
Schering Corp |
Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
|
AU7472896A
(en)
*
|
1995-11-02 |
1997-05-22 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
|
WO1997030707A1
(en)
|
1996-02-23 |
1997-08-28 |
Eli Lilly And Company |
NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(en)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
METHOD FOR MANUFACTURING A NON-REPRODUCIBLE PATTERNED FILM BY OPTICAL READING FOR THE PROTECTION OF DOCUMENTS
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
EP1137634B1
(en)
*
|
1998-12-07 |
2005-06-15 |
Schering Corporation |
Process for the synthesis of azetidinones
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
EA004231B1
(en)
*
|
1998-12-23 |
2004-02-26 |
Джи.Ди.Сирл Ллс |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
BR9916564A
(en)
*
|
1998-12-23 |
2002-01-29 |
Searle Llc |
Combinations for cardiovascular indications
|
HUP0201972A3
(en)
*
|
1998-12-23 |
2005-06-28 |
G D Searle Llc Chicago |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
ES2189529T3
(en)
*
|
1998-12-23 |
2003-07-01 |
Searle Llc |
INHIBITOR COMBINATIONS FOR THE TRANSPORT OF BILIAR ACIDS IN THE ILEON AND COMPLEXING AGENTS FOR CARDIOVASCULAR INDICATIONS.
|
PT1140184E
(en)
*
|
1998-12-23 |
2003-10-31 |
Searle Llc |
COMBINATIONS OF ESTER TRANSFER PROTEIN INHIBITORS OF CHOLESTEROL WITH NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS
|
BR9916565A
(en)
*
|
1998-12-23 |
2002-01-29 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
|
WO2000038722A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
|
EP1340510A1
(en)
|
1998-12-23 |
2003-09-03 |
G.D. Searle LLC. |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
WO2000060107A1
(en)
|
1999-04-05 |
2000-10-12 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1 - (4-fluorophenyl) - 3(r)-[3(s) - hydroxy-3 - (4-fluorophenyl) propyl)]-4(s) - (4-hydroxyphenyl)-2-azetidinone
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
AU2001247331A1
(en)
*
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
AU2001240115A1
(en)
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
WO2002036124A2
(en)
*
|
2000-10-30 |
2002-05-10 |
Schering Corporation |
Treatment and method using loratadine and montelukast
|
EP1593670B1
(en)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP1510521A1
(en)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
|
CA2432798C
(en)
|
2000-12-20 |
2007-02-27 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
SK7822003A3
(en)
*
|
2000-12-21 |
2003-12-02 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
RS51449B
(en)
*
|
2001-01-26 |
2011-04-30 |
Schering Corporation |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
TW200840563A
(en)
*
|
2001-01-26 |
2008-10-16 |
Schering Corp |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
|
NZ542090A
(en)
*
|
2001-01-26 |
2006-09-29 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
CZ20032031A3
(en)
*
|
2001-01-26 |
2003-12-17 |
Schering Corporation |
Pharmaceutical preparation
|
US20030053981A1
(en)
*
|
2001-01-26 |
2003-03-20 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
CA2434430A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
EP1911462A3
(en)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Compositions comprising a sterol absorption inhibitor
|
TWI291957B
(en)
*
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
BRPI0208384B1
(en)
|
2001-03-28 |
2016-05-31 |
Merck Sharp & Dohme |
enantioselective synthesis of azetidinone intermediate compounds
|
US20030013699A1
(en)
*
|
2001-05-25 |
2003-01-16 |
Davis Harry R. |
Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
EP1859796A3
(en)
*
|
2001-09-21 |
2008-07-02 |
Schering Corporation |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
DE60216300T2
(en)
*
|
2001-09-21 |
2007-06-28 |
Schering Corp. |
TREATMENT OF XANTHOM BY AZETIDINONE DERIVATIVES AS AN INHIBITOR OF STEROL ABSORPTION
|
WO2003040127A1
(en)
*
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
|
KR20050044352A
(en)
*
|
2001-11-09 |
2005-05-12 |
아테로제닉스, 인코포레이티드 |
Methods of reversing and preventing cardiovascular pathologies
|
US7202247B2
(en)
|
2001-12-19 |
2007-04-10 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
CN1596240A
(en)
*
|
2001-12-19 |
2005-03-16 |
阿特罗吉尼克斯公司 |
Chalcone derivatives and their use to treat diseases
|
FR2833842B1
(en)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES
|
CA2471639A1
(en)
|
2002-01-17 |
2003-07-31 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
WO2003074101A1
(en)
*
|
2002-02-28 |
2003-09-12 |
Eli Lilly And Company |
Method of treating atherosclerosis and hypercholesterolemia
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(en)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Acid group-substituted diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
WO2004004665A2
(en)
*
|
2002-07-09 |
2004-01-15 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(en)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
|
US6933292B2
(en)
|
2002-07-30 |
2005-08-23 |
Children's Medical Center Corporation |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
AU2003303239A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
DE602004018617D1
(en)
|
2003-03-07 |
2009-02-05 |
Schering Corp |
SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
|
CN1756755A
(en)
*
|
2003-03-07 |
2006-04-05 |
先灵公司 |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
JP5137228B2
(en)
*
|
2003-03-07 |
2013-02-06 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Substituted azetidinone compounds, substituted azetidinone formulations and their use for the treatment of hypercholesterolemia
|
WO2004099132A2
(en)
*
|
2003-05-05 |
2004-11-18 |
Ranbaxy Laboratories Limited |
Process for the preparation of trans-isomers of diphenylazetidinone derivatives
|
AR041089A1
(en)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS
|
AP2501A
(en)
*
|
2003-05-30 |
2012-10-22 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives
|
WO2005000217A2
(en)
*
|
2003-06-06 |
2005-01-06 |
Merck & Co., Inc. |
Combination therapy for the treatment of dyslipidemia
|
AU2004259747B2
(en)
*
|
2003-07-24 |
2009-02-19 |
Merck Frosst Canada Ltd |
Diphenyl substituted Cycloalkanes, compositions containing such compounds and methods of use
|
AU2003259547A1
(en)
*
|
2003-07-31 |
2005-02-14 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
EP1522541A1
(en)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Novel hypocholesterolemic compounds
|
WO2005042692A2
(en)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
|
WO2005046797A2
(en)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
EP1918000A2
(en)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
WO2005047248A1
(en)
*
|
2003-11-10 |
2005-05-26 |
Microbia, Inc. |
4-biarylyl-1-phenylazetidin-2-ones
|
WO2005049592A1
(en)
*
|
2003-11-24 |
2005-06-02 |
Hetero Drugs Limited |
A novel process for ezetimibe intermediate
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
AU2004308332B2
(en)
*
|
2003-12-23 |
2008-04-10 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
ATE485267T1
(en)
*
|
2003-12-23 |
2010-11-15 |
Astrazeneca Ab |
DIPHENYLAZETIDINONE DERIVATIVES WITH CHOLESTERINE ABSORPTION INHIBITING EFFECT
|
MXPA06008124A
(en)
*
|
2004-01-16 |
2007-01-26 |
Merck & Co Inc |
Npc1l1 (npc3) and methods of identifying ligands thereof.
|
EP1725234B2
(en)
*
|
2004-03-05 |
2016-02-24 |
The Trustees of The University of Pennsylvania |
Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
PL1756049T3
(en)
*
|
2004-05-21 |
2008-02-29 |
Sanofi Aventis Deutschland |
Method for producing 1,4-diphenyl azetidinone derivatives
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
WO2006004903A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Atherogenics, Inc. |
1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
AR050631A1
(en)
*
|
2004-09-09 |
2006-11-08 |
Novartis Ag |
COMBINATION OF ORGANIC COMPOUNDS
|
WO2006039334A1
(en)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinations of substituted azetidonones and cb1 antagonists
|
AU2005311930B9
(en)
|
2004-12-03 |
2009-09-10 |
Merck Sharp & Dohme Corp. |
Substituted piperazines as CB1 antagonists
|
EP1834180A2
(en)
*
|
2004-12-15 |
2007-09-19 |
Schering Corporation |
Functional assays for cholesterol absorption inhibitors
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
MX2007012253A
(en)
|
2005-04-04 |
2007-12-07 |
Univ Pontificia Catolica Chile |
The use of ezetimibe in the prevention and treatment of cholesterol gallstones.
|
TW200726746A
(en)
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
KR20080023296A
(en)
*
|
2005-05-09 |
2008-03-13 |
마이크로비아 인코포레이티드 |
Organometal benzenephosphonate coupling agents
|
AU2006244043A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Microbia, Inc. |
Processes for production of phenolic 4-biphenylylazetidin-2-ones
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
CN101222950A
(en)
*
|
2005-05-25 |
2008-07-16 |
迈克罗比亚公司 |
Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
|
JP2008543837A
(en)
*
|
2005-06-15 |
2008-12-04 |
メルク エンド カムパニー インコーポレーテッド |
Anti-hypercholesterolemic compound
|
WO2007001975A1
(en)
*
|
2005-06-20 |
2007-01-04 |
Schering Corporation |
Piperidine derivatives useful as histamine h3 antagonists
|
AR054482A1
(en)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
DERIVATIVES OF AZETIDINONE FOR THE TREATMENT OF HYPERLIPIDEMIAS
|
EP1893570A4
(en)
*
|
2005-06-22 |
2009-12-23 |
Reddy Manne Satynarayana |
Improved process for the preparation of ezetimibe
|
SA06270191B1
(en)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
|
EP1741427A1
(en)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmaceutical composition comprising simvastatin and ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
CA2616058A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Vinod Kumar Kansal |
Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
CA2625416A1
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
EP1948599A1
(en)
*
|
2005-11-08 |
2008-07-30 |
Ranbaxy Laboratories Limited |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
HUP0501164A2
(en)
*
|
2005-12-20 |
2007-07-30 |
Richter Gedeon Nyrt |
New industrial process for the production of ezetimibe
|
MX2008008340A
(en)
*
|
2005-12-21 |
2008-09-03 |
Schering Corp |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist.
|
US20090227786A1
(en)
*
|
2005-12-22 |
2009-09-10 |
Ana Gavalda I Escude |
Processes for preparing intermediate compounds useful for the preparation of ezetimibe
|
PE20071320A1
(en)
|
2006-01-18 |
2007-12-29 |
Schering Corp |
CANNABINOID RECEPTOR MODULATORS
|
US7956182B2
(en)
*
|
2006-02-16 |
2011-06-07 |
Kotobuki Pharmaceutical Co., Ltd. |
Process for preparing optically active alcohols
|
US7910698B2
(en)
*
|
2006-02-24 |
2011-03-22 |
Schering Corporation |
NPC1L1 orthologues
|
US20070275075A1
(en)
*
|
2006-03-06 |
2007-11-29 |
Ilan Zalit |
Ezetimibe compositions
|
AR059838A1
(en)
*
|
2006-03-14 |
2008-04-30 |
Ranbaxy Lab Ltd |
FORMULATIONS FOR STABILIZING DOSES OF STATIN
|
WO2007120824A2
(en)
*
|
2006-04-10 |
2007-10-25 |
Teva Pharmaceutical Industries Ltd. |
Processes for the synthesis of azetidinone
|
AR060623A1
(en)
*
|
2006-04-27 |
2008-07-02 |
Astrazeneca Ab |
COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
TW200811101A
(en)
*
|
2006-07-14 |
2008-03-01 |
Ranbaxy Lab Ltd |
Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
|
WO2008027081A1
(en)
*
|
2006-08-29 |
2008-03-06 |
Teva Pharmaceutical Industries Ltd. |
Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl] azetidin-2-one
|
JP2010502702A
(en)
*
|
2006-09-05 |
2010-01-28 |
シェーリング コーポレイション |
Pharmaceutical composition for use in lipid management and therapeutic treatment of atherosclerosis and fatty liver
|
EP2091534A1
(en)
*
|
2006-09-15 |
2009-08-26 |
Schering Corporation |
Azetidinone derivatives and methods of use thereof
|
CA2663504A1
(en)
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
|
CN101528746A
(en)
*
|
2006-09-15 |
2009-09-09 |
先灵公司 |
Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
|
WO2008033464A2
(en)
*
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Azetidinone derivatives for the treatment of disorders of the lipid metabolism
|
US7638526B2
(en)
*
|
2006-09-15 |
2009-12-29 |
Schering Corporation |
Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(en)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
Azetidinone derivative and synthetic method thereof
|
AU2007342603A1
(en)
*
|
2006-12-20 |
2008-07-17 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
EP1939174A1
(en)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Inclusion complex of ezetimibe and a cyclodextrin and processes in the preparation thereof
|
US20080161279A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Wisler Gerald L |
Methods of Treating Obesity
|
EP2125715A2
(en)
*
|
2007-01-24 |
2009-12-02 |
Krka |
Process for the preparation of ezetimibe and derivatives thereof
|
WO2008096372A2
(en)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Process for preparing highly pure ezetimibe using novel intermediates
|
WO2008104875A1
(en)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones as cholesterol absorption inhibitors
|
US20100125059A1
(en)
|
2007-03-06 |
2010-05-20 |
Teijin Pharma Limited |
1-biarylazetidinone derivative
|
EP2134169A2
(en)
|
2007-03-09 |
2009-12-23 |
Indigene Pharmaceuticals Inc. |
Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
WO2008123953A1
(en)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compound
|
WO2008130616A2
(en)
*
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
JP2010529148A
(en)
*
|
2007-06-07 |
2010-08-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
Reduction method for the production of ezetimibe
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
NZ582249A
(en)
*
|
2007-06-28 |
2012-06-29 |
Intervet Int Bv |
Substituted piperazines as cb1 antagonists
|
EP2170847A2
(en)
*
|
2007-06-28 |
2010-04-07 |
Intervet International BV |
Substituted piperazines as cb1 antagonists
|
CA2694378A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Cipla Limited |
Pharmaceutical compositions and process for making them
|
WO2009024889A2
(en)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
|
WO2009027785A2
(en)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
1, 3-oxazole derivatives as cetp inhibitors
|
WO2009032264A1
(en)
*
|
2007-08-30 |
2009-03-12 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing intermediates of ezetimibe by microbial reduction
|
DE102007054497B3
(en)
*
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia
|
ES2639995T3
(en)
|
2007-12-10 |
2017-10-31 |
Ratiopharm Gmbh |
Pharmaceutical formulation comprising ezetimibe
|
CZ305066B6
(en)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Process for preparing (3R, 4S)-l-(4-fiuorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3- hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone
|
EP2128133A1
(en)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Ezetimibe process and composition
|
JP2011521992A
(en)
*
|
2008-06-06 |
2011-07-28 |
ニコックス エス エイ |
Composition comprising atorvastatin 4- (nitroxy) butyl ester and a lipid lowering agent
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
SG10201404330VA
(en)
|
2008-08-29 |
2014-10-30 |
Codexis Inc |
Ketoreductase Polypeptides For The Stereoselective Production Of (4S)-3[(5S)-5(4-Fluorophenyl)-5-Hydroxypentanoyl]-4-Phenyl-1,3-Oxazolidin-2-One
|
AU2009315314B2
(en)
|
2008-11-14 |
2013-04-18 |
Bomi P. Framroze |
A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
|
EP2204170A1
(en)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Pharmaceutical composition comprising ezetimibe and simvastatin
|
WO2010075068A1
(en)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
WO2010075069A1
(en)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
EP2216016A1
(en)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Process for the preparation of a pharmaceutical composition comprising ezetimibe
|
WO2010100255A1
(en)
|
2009-03-06 |
2010-09-10 |
Lipideon Biotechnology Ag |
Pharmaceutical hypocholesterolemic compositions
|
ATE536172T1
(en)
|
2009-03-13 |
2011-12-15 |
Sanovel Ilac Sanayi Ve Ticaret As |
EZETIMIBE COMPOSITIONS
|
WO2010113182A1
(en)
|
2009-03-31 |
2010-10-07 |
Lupin Limited |
Intermediates in the preparation of 1,4-diphenyl azetidinone
|
CA2757722C
(en)
|
2009-04-01 |
2018-05-22 |
Matrix Laboratories Ltd. |
Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
|
WO2011002424A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility and stability enchancing pharmaceutical formulation
|
WO2011002422A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility enhancing pharmaceutical formulation
|
EP2448919A2
(en)
|
2009-07-02 |
2012-05-09 |
Mahmut Bilgic |
Solubility and stability enchancing pharmaceutical formulation
|
CN101993403B
(en)
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
Azetidinone compound and medical applications thereof
|
ES2575560T3
(en)
|
2009-08-19 |
2016-06-29 |
Codexis, Inc. |
Cetorreductase polypeptides to prepare phenylephrine
|
EP3130343B1
(en)
|
2010-02-24 |
2018-05-09 |
Relypsa, Inc. |
Polyimidazoles for use as bile acid sequestrants
|
CN102906159B
(en)
|
2010-02-24 |
2017-09-26 |
瑞立普萨公司 |
Amine polymer as bile acid sequestrant
|
WO2011106542A2
(en)
|
2010-02-24 |
2011-09-01 |
Relypsa, Inc. |
Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants
|
EP2368543A1
(en)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
|
DK2561069T3
(en)
|
2010-04-23 |
2017-05-01 |
Alexion Pharma Inc |
Enzyme for lysosomal storage disease
|
US9040262B2
(en)
|
2010-05-04 |
2015-05-26 |
Codexis, Inc. |
Biocatalysts for ezetimibe synthesis
|
ES2372460B1
(en)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
NEW METHOD FOR THE PREPARATION OF EZETIMIBA.
|
US8663631B2
(en)
|
2010-09-09 |
2014-03-04 |
Synageva Biopharma Corporation |
Methods for treating lysosomal acid lipase deficiency in patients
|
SG190029A1
(en)
|
2010-11-08 |
2013-06-28 |
Albireo Ab |
Ibat inhibitors for the treatment of liver diseases
|
PT2637646T
(en)
|
2010-11-08 |
2016-08-17 |
Albireo Ab |
A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
|
WO2012076030A1
(en)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
|
EP2675472A4
(en)
|
2011-02-15 |
2014-09-17 |
Synageva Biopharma Corp |
Methods for treating lysosomal acid lipase deficiency
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(en)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Improved process for the preparation of ezetimibe
|
PL231215B1
(en)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Process for the preparation of substituted azetidinones and intermediates for the synthesis thereof
|
CN102675177A
(en)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
Preparation methods of blood fat lowering medicament and key intermediates of blood fat lowering medicament
|
CN102952055A
(en)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
Preparation method of ezetimibe and its intermediate
|
CN103204795B
(en)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
A kind of preparation method of chirality azetidinones
|
DK2844233T3
(en)
|
2012-05-01 |
2020-07-13 |
Althera Life Sciences Llc |
ORAL TABLE CONSTRUCTION CONSISTING OF A PROVIDED COMBINATION OF ROSUVASTATIN AND EZETIMIB FOR THE TREATMENT OF HYPERLIPIDIA AND CARDIOVASCULAR DISEASES
|
CN103570574B
(en)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
Intermediate used in a kind of synthetic method of ezetimibe and the method
|
CN103102297A
(en)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
Synthesis method of novel atorvastatin
|
TW201427658A
(en)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
|
CN103864708A
(en)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
Preparation method of ezetimibe intermediate
|
WO2015039675A1
(en)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Novel process for the preparation of ezetimibe intermediates
|
WO2015066252A1
(en)
|
2013-11-04 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions thereof, and methods of use
|
US9926269B2
(en)
|
2013-12-18 |
2018-03-27 |
Rudjer Boskovic Institute |
Beta-lactam cholesterol absorption inhibitors
|
CN103739537B
(en)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
New synthesis method of ezetimibe
|
KR20150079373A
(en)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
Composite formulation for oral administration comprising ezetimibe and rosuvastatin
|
CN103755616A
(en)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
Method for preparing ezetimibe isomer
|
CN106572997A
(en)
|
2014-05-30 |
2017-04-19 |
辉瑞公司 |
Carbonitrile derivatives as selective androgen receptor modulators
|
CN105294426B
(en)
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
Azetidinone compounds Preparation Method And Their Intermediate
|
CN104447474A
(en)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
Synthetic method of ezetimibe isomer
|
CN104387308A
(en)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
Method for preparing high-purity ezetimibe by controlling generation of EZ-zanOH impurity
|
CN104513187B
(en)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
The synthetic method of Ezetimibe and its intermediate
|
JP2016145173A
(en)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
Method for producing (3r,4s)-1-(4-fluorophenyl)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl]-(4-hydroxyphenyl)-2-azetidinone
|
RU2022102472A
(en)
|
2015-03-13 |
2022-03-15 |
Эсперион Терапеутикс, Инк. |
FIXED COMBINATIONS AND COMPOSITIONS CONTAINING ETC-1002 AND EZETIMIB AND METHODS FOR THE TREATMENT OR REDUCTION OF THE RISK OF CARDIOVASCULAR DISEASE DEVELOPMENT
|
MA41793A
(en)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
FIXED DOSE ASSOCIATIONS INCLUDING ETC1002 AND ONE OR MORE STATINS TO TREAT OR REDUCE A CARDIOVASCULAR RISK
|
CN105287513A
(en)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
Ezetimibe medicine composition and preparation method thereof
|
CN107098841A
(en)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
Intermediate used in the preparation method and this method of a kind of Ezetimibe
|
WO2018103642A1
(en)
|
2016-12-05 |
2018-06-14 |
Patsnap |
Systems, apparatuses, and methods for searching and displaying information available in large databases according to the similarity of chemical structures discussed in them
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(en)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Pharmaceutical composition comprising ezetimibe
|
CN111655971A
(en)
|
2018-01-16 |
2020-09-11 |
Qed环境系统有限责任公司 |
Fluid level monitoring system and method incorporating a pressure sensor system with an inflatable/collapsible bag
|
EP3942048A1
(en)
|
2019-03-20 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors
|
CA3133002A1
(en)
|
2019-03-20 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
|
WO2021019499A1
(en)
|
2019-07-31 |
2021-02-04 |
TECNIMEDE - Sociedade Técnico-medicinal, SA |
Solid oral multiple-unit immediate release compositions, methods and uses thereof
|
WO2022023206A1
(en)
|
2020-07-27 |
2022-02-03 |
Krka, D.D., Novo Mesto |
Bilayer tablet comprising ezetimibe and atorvastatin
|
CA3222897A1
(en)
*
|
2021-06-17 |
2022-12-22 |
Xufei LI |
Hybutimibe intermediate and preparation method therefor
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|